Disulfiram Plus Nivolumab in Patients with Advanced Gastric Cancer: An Open-Label Phase I Trial

ABSTRACT: Tumor-associated macrophages correlate with poor prognosis and resistance to immune checkpoint inhibitor therapy in cancer patients. Disulfiram, a drug for alcoholism treatment, has been identified as an inhibitor for FROUNT, which facilitates chemokine-mediated macrophage accumulation to tumor sites. A combination of disulfiram with a PD-1 antibody synergistically inhibits tumor progression in the mouse model. Here, we performed the single-cell transcriptome analysis of gastric cancer specimens before and after treatment with disulfiram plus nivolumab. We explored the immunophenotypical features associated with the response to the treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE189926 | GEO | 2022/11/27

REPOSITORIES: GEO